Drug companies reported paying U.S. prescribers $3.28 billion in non-research payments during 2023 alone, according to a major Cochrane review published on October 9, 2026. The findings reveal that pharmaceutical gifts, free meals, and payments to doctors lead to inappropriate prescribing, higher prescription volumes, and costlier medications across 93 studies involving millions of prescribers.
Medical professionals often maintain that small perks carry no personal influence. Empirical data tells a different story. According to the review led by pharmacy professor Barbara Mintzes, gifts and payments from drug manufacturers directly alter clinical habits.
How Pharmaceutical Marketing Drives Up Prescription Costs
The international systematic review investigated the relationship between industry marketing and real-world prescribing behavior across millions of healthcare providers. Researchers categorized industry interactions into advertising and education, gifts and payments, and free drug samples. Among these categories, gifts and payments demonstrated a consistent link to increased prescription volume and decreased appropriateness.
Doctors exposed to pharmaceutical advertising and sales representative visits tended to prescribe treatments that were less suitable or cost more than equivalent generic alternatives.
“Doctors often think that … they can’t be bought for the price of a sandwich but the data shows this is an effective marketing strategy. The more free meals a doctor receives, the more likely they are to prescribe less appropriate or more expensive drugs.”
Barbara Mintzes, University of Sydney
The analysis documented a striking dose-response pattern.
For medications spanning antidepressants, cholesterol treatments, high blood pressure management, and opioid painkillers, prescribing rates climbed in direct proportion to the number of complimentary meals a physician accepted. Dr. Lisa Bero, a University of Colorado Anschutz medicine professor and senior author of the review, explained that when physicians have greater exposure to drug company promotions, prescribing tends to become less appropriate, more frequent, and more expensive. Dr. Bero and Barbara Mintzes discussed the findings alongside other researchers during a technical briefing, where they highlighted that these promotional strategies affect patient care directly by encouraging the use of featured medicines more often and to wider patient groups than necessary.
Other co-authors of the review include Joel Lexchin, a professor emeritus at York University’s Faculty of Health; Geoff Spurling, an associate professor at the University of Queensland; Riaz Qureshi, an assistant professor at the University of Colorado Anschutz Medical Campus; and Lisa Bero in her role as professor of medicine and public health at the Center for Bioethics and Humanities, University of Colorado Anschutz Medical Campus. Additional co-authors and contributors include researchers from institutions across the United States, Canada, Australia, and the United Kingdom.
Drug Companies Paid U.S. Prescribers Billions in Non-Research Payments
The research relied heavily on public transparency databases that track financial transfers between commercial drug companies and medical practitioners.
Federal disclosures show that drug companies reported paying U.S. prescribers $3.28 billion in non-research payments during 2023 alone, with meals exceeding $250 million in 2022. International jurisdictions show comparable trends. In France, public records via Transparence Santé enabled researchers to examine prescribing records for more than 41,000 family doctors, revealing that gift recipients issued higher numbers of prescriptions.
In the United Kingdom, pharma companies disclosed £647.3m in research and development payments in 2025, accounting for roughly 70 percent of total disclosed transfers of value. Australian doctors received AU$148.7 million from pharmaceutical companies between 2015 and 2024 for conferences, travel, or consultancy fees.
Institutional Safeguards Improve the Appropriateness of Drug Prescriptions
Despite widespread industry engagement, the review identified encouraging evidence regarding institutional safeguards. Conflict-of-interest policies successfully improved the appropriateness of drug prescriptions.
Experts stress that addressing commercial influence requires systemic institutional changes rather than placing the burden entirely on individual clinicians. Quinn Grundy emphasized that healthcare organizations must establish protective practice environments.
“These studies show that we can create practice environments that promote and preserve independence and that this is best achieved collectively, within health systems and institutions, rather than leaving it up to individual clinicians.”
Quinn Grundy
While transparency laws illuminate financial ties in countries like the U.S. and France, other nations lack mandatory disclosure mechanisms. In Canada, where no federal tracking law exists, manufacturers like GSK Canada voluntarily disclose partial breakdowns, such as the $18.9-million it paid in 2025 to health care professionals and corporations. Researchers and public health advocates continue to urge adoption of strict internal policies and public reporting frameworks to ensure clinical decisions remain grounded purely in evidence.
In Canada, manufacturers like GSK Canada voluntarily disclose partial breakdowns, such as the $18.9-million it paid in 2025 to health care professionals and corporations.